Senseonics Holdings, Inc. (SENS)
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Senseonics Holdings, Inc. Common Stock (NASDAQ: SENS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two
Wall Street Analysts Predict a 124.49% Upside in Senseonics (SENS): Here's What You Should Know
The consensus price target hints at a 124.5% upside potential for Senseonics (SENS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.
SENS Eversense 365 Integrated With twiist Gains Full Availability
Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
All You Need to Know About Senseonics (SENS) Rating Upgrade to Buy
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics (SENS) Moves 5.3% Higher: Will This Strength Last?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval
Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.
SENS Stock Up as Eversense 365 Enters AID Market With twiist System
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
Senseonics: Eversense 365 Is A Game Changer For The CGM Industry
Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.
Senseonics Holdings, Inc. (SENS) Q3 2025 Earnings Call Transcript
Senseonics Holdings, Inc. ( SENS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Matthew Miksic - Barclays Bank PLC, Research Division Joshua Jennings - TD Cowen, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's Senseonics Third Quarter 2025 Earnings Conference Call.
Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.8 per share a year ago.
